Orchestrated Action of AMPK Activation and Combined VEGF/PD-1 Blockade with Lipid Metabolic Tunning as Multi-Target Therapeutics against Ovarian Cancers
Open Access
- 20 June 2022
- journal article
- review article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 23 (12) , 6857
Abstract
Ovarian cancer is one of the most lethal gynecological malignancies worldwide, and chemoresistance is a critical obstacle in the clinical management of the disease. Recent studies have suggested that exploiting cancer cell metabolism by applying AMP-activated protein kinase (AMPK)-activating agents and distinctive adjuvant targeted therapies can be a plausible alternative approach in cancer treatment. Therefore, the perspectives about the combination of AMPK activators together with VEGF/PD-1 blockade as a dual-targeted therapy against ovarian cancer were discussed herein. Additionally, ferroptosis, a non-apoptotic regulated cell death triggered by the availability of redox-active iron, have been proposed to be governed by multiple layers of metabolic signalings and can be synergized with immunotherapies. To this end, ferroptosis initiating therapies (FITs) and metabolic rewiring and immunotherapeutic approaches may have substantial clinical potential in combating ovarian cancer development and progression. It is hoped that the viewpoints deliberated in this review would accelerate the translation of remedial concepts into clinical trials and improve the effectiveness of ovarian cancer treatment.Keywords
Funding Information
- Science, Technology, and Innovation Commission of Shenzhen Municipality—Basic Research Programme (JCYJ20170815105918719, 17121220, R4015-19)
- RGC General Research Fund (GRF) of Hong Kong (JCYJ20170815105918719, 17121220, R4015-19)
This publication has 147 references indexed in Scilit:
- Activation of AMPK inhibits cervical cancer cell growth through AKT/FOXO3a/FOXM1 signaling cascadeBMC Cancer, 2013
- AMPK Is a Negative Regulator of the Warburg Effect and Suppresses Tumor Growth In VivoCell Metabolism, 2013
- Bevacizumab and ovarian cancerTherapeutic Advances in Medical Oncology, 2012
- The dark face of AMPK as an essential tumor promoterCellular Logistics, 2012
- AMPK regulates NADPH homeostasis to promote tumour cell survival during energy stressNature, 2012
- Tumor heterogeneity: Causes and consequencesBiochimica et Biophysica Acta (BBA) - Reviews on Cancer, 2010
- mTOR regulates memory CD8 T-cell differentiationNature, 2009
- Inhibition of Cervical Cancer Cell Growth through Activation of Upstream Kinases of AMP-Activated Protein KinaseTumor Biology, 2009
- Cytotoxic effect of 5-aminoimidazole-4-carboxamide-1-β-4-ribofuranoside (AICAR) on childhood acute lymphoblastic leukemia (ALL) cells: implication for targeted therapyMolecular Cancer, 2007
- Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+T lymphocytes are prognostic factors of human ovarian cancerProceedings of the National Academy of Sciences, 2007